Why Most Supplement Claims Won’t Survive FDA Scrutiny —
And What to Do About It
Supplement brands can make structure/function claims without pre-market FDA approval. But those claims still require competent and reliable scientific evidence — and most brands do not realise that the evidence they are relying on does not actually match their product, dose, ingredient form, or consumer population.
← Back to InsightsDSHEA gives supplement brands significant freedom — but it does not protect them from FDA enforcement, FTC action, or retailer rejection when their scientific evidence does not actually support their specific product claims. This article explains exactly where the evidentiary gap occurs, what regulators look for, and the six practical steps every brand should take before going to market.
Here’s the Problem
Under DSHEA, supplement brands do not need pre-market FDA approval to make structure/function claims — statements like “supports immune health” or “promotes digestive balance.” This creates a common but dangerous misunderstanding: that freedom from pre-market approval means freedom from evidentiary requirements.
It does not. The FDA still requires that structure/function claims be supported by competent and reliable scientific evidence. The FTC applies the same standard to advertising. And increasingly, major retailers are running their own scientific compliance reviews before a product reaches the shelf.
The real problem is not that brands lack evidence. It is that the evidence they use does not match their actual product. A study conducted on one ingredient, at one dose, in one population, does not automatically validate a different ingredient, a different dose, or a different formulation — even if the claim sounds identical.
Why It Matters
The risk is not theoretical. Brands that cannot substantiate their claims face:
- FDA warning letters requiring immediate label or marketing changes
- FTC enforcement action targeting advertising and digital claims
- Retailer delisting or compliance holds that block market access
- Consumer litigation exposure when claims are found to be unsupported
- Investor and partner due diligence that surfaces evidentiary gaps
- Launch delays while substantiation is rebuilt under deadline pressure
In most cases, these problems are entirely preventable — but only if the substantiation work is done before launch, not after a challenge arrives.
“The evidence does not need to be perfect. It needs to match the product, the claim, and the population — and it needs to be documented before anyone asks for it.”
A Real Example: The Probiotic Problem
Consider a brand selling a probiotic supplement claiming to “support digestive health.” The scientific team cites a published clinical trial — but the trial used a different probiotic strain, at ten times the CFU dose, in a patient population with diagnosed gastrointestinal conditions.
Probiotic science is strain-specific. A well-studied strain like Lactobacillus rhamnosus GG at 10 billion CFU does not substantiate a claim made for a different strain at 1 billion CFU in a healthy adult population. Dose, strain, formulation, and population are all material — and regulators, retailers, and opposing experts know to look for each one.
What Regulators Actually Look For
Whether it is an FDA review, an FTC investigation, or a retailer compliance assessment, the core question is always the same: does the evidence support this specific claim, for this specific product, at this specific dose, in this intended population?
| Question | Why it matters |
|---|---|
| What exactly is the claim? | Vague claims are harder to substantiate and harder to defend |
| What ingredient or strain was studied? | Evidence is ingredient- and strain-specific — not category-wide |
| What dose was used in the study? | A different dose in your product requires separate justification |
| Who was studied? | Patient populations do not automatically generalise to healthy consumers |
| Was the outcome relevant to the claim? | A surrogate endpoint is not always equivalent to the claimed benefit |
| Are the conclusions proportionate? | Overstating what the science shows is itself an evidentiary failure |
What to Do
- Define each claim precisely before it appears on a label, website, or in any marketing material
- Map each claim to the exact evidence supporting it — not general category evidence
- Verify that the evidence matches your product’s dose, ingredient form, strain, and intended population
- Identify evidentiary gaps before launch or retailer review — not after a challenge arrives
- Build a documented substantiation file before a warning letter, retailer compliance hold, or legal inquiry forces you to
- Use independent scientific review when claims are commercially central, high-risk, or in a contested regulatory area
The organisations that navigate this environment successfully treat scientific evidence as a managed asset — reviewed before claims are made, documented before they are challenged, and updated as the science evolves. That discipline is not expensive relative to the cost of getting it wrong.
- Federal Trade Commission. Health Products Compliance Guidance. FTC, 2022.
- U.S. Food & Drug Administration. Dietary Supplements: Structure/Function Claims. FDA, 2023.
- Guyatt GH et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924.
- Hill C et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology. 2014;11:506–514.
Five things this article establishes
- 1 DSHEA permits structure/function claims without pre-market approval — but not without competent and reliable scientific evidence.
- 2 The most common evidentiary failure is a mismatch between the evidence cited and the actual product, dose, strain, or population.
- 3 FDA, FTC, retailers, and litigants all ask the same core question: does this evidence support this specific product and this specific claim?
- 4 Substantiation work done before launch is significantly less costly than substantiation work done under enforcement pressure.
- 5 Independent scientific review adds the most value when claims are commercially central, high-risk, or operating in a contested regulatory area.
Explore our scientific services
Browse the full range of FSC’s independent scientific consulting services and resources.
Explore Our Services